This article is more than 5 years old. Information may no longer be current.
Ocular Therapeutix to begin glaucoma treatment study
Click Here to Manage Email Alerts
The feasibility of a sustained-release travoprost-loaded punctum plug for the treatment of glaucoma will be examined in a study by Ocular Therapeutix, the company announced in a press release.
Up to 20 patients with documented ocular hypertension or open-angle glaucoma will be enrolled in the study, which will take place at Singapore National Eye Center and the National University Hospital in Singapore, according to the release.
“Positive results from this study will establish efficacy of our resorbable travoprost-loaded punctum plug technology, providing a stepping stone for advancements of this product with longer-term therapies” Amar Sawhney, PhD, president and CEO of Ocular Therapeutix, said in the release.
Primary endpoints for the study are retention of the plug through 30 days and reduction of IOP from baseline.
The travoprost-loaded plugs use the company’s proprietary polyethylene glycol hydrogel technology to sustain release of the drug, according to the release. The plugs degrade at the end of the treatment period and exit via the nasolacrimal system without physician intervention.